Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$11.93
+1.6%
$10.09
$3.47
$12.43
$1.78B1.831.64 million shs2.20 million shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$7.80
+6.1%
$8.08
$6.85
$21.01
$433.76M-0.08513,271 shs357,478 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$19.37
+1.8%
$32.76
$16.88
$154.13
$1.87B0.452.22 million shs4.00 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$41.29
+4.0%
$42.71
$20.08
$57.28
$1.67B0.8683,010 shs613,835 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+1.62%+3.92%+14.16%+54.53%+237.01%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+6.12%+0.52%-10.96%+2.90%-51.67%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.79%+6.49%-51.22%-61.50%-87.11%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
+4.03%+2.08%-4.22%-6.41%+45.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
3.417 of 5 stars
1.43.00.04.23.02.50.6
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
1.884 of 5 stars
3.51.00.00.01.41.70.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7527 of 5 stars
4.22.00.04.22.91.71.9
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
1.8494 of 5 stars
3.50.00.00.02.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.86
Moderate Buy$10.57-11.39% Downside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$30.00284.62% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.44
Hold$60.88214.27% Upside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
3.00
Buy$66.6761.46% Upside

Current Analyst Ratings Breakdown

Latest CGEM, ADPT, SRPT, and TARS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.00
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
6/18/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.00
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$24.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$50.00 ➝ $25.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$29.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M10.13N/AN/A$1.37 per share8.71
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B1.00$2.48 per share7.81$15.99 per share1.21
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$182.95M9.48N/AN/A$5.87 per share7.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%7/30/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$2.69N/A1.77N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)

Latest CGEM, ADPT, SRPT, and TARS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7951N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.41N/AN/AN/A$95.81 millionN/A
5/8/2025Q1 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.78-$0.74+$0.04-$0.74N/AN/A
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
5/1/2025Q1 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
5/1/2025Q1 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.92
2.82
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
11.62
11.62
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.00
4.02
2.46
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
5.57
5.54

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790151.92 million142.19 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.01 million54.79 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37298.28 million90.71 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5042.01 million38.25 millionOptionable

Recent News About These Companies

Tarsus to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$11.93 +0.19 (+1.62%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$12.12 +0.19 (+1.59%)
As of 07/9/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$7.80 +0.45 (+6.12%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$7.92 +0.12 (+1.59%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$19.37 +0.34 (+1.79%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$19.52 +0.15 (+0.77%)
As of 06:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$41.29 +1.60 (+4.03%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$41.28 -0.02 (-0.04%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.